Tirelizumab
Oral Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Oral Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide M.D. Anderson Cancer Center | Phase 2 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2 | B |
Carboplatin Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | CCC |
Epirubicin Loren Mell, MD | Phase 2 | CCC |
Pembrolizumab Loren Mell, MD | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
Tirelizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →